Clinical trial · Observational
Research on the Role of SLC1A5 in the Development of Esophageal Cancer
Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer
NCT02633436CI-TRIAL-00023481unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Amino Acid Transport Disorder | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SLC1A5 expression | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cancer tissues
- description
- SLC1A5 expression of esophageal cancer tissues from patients
- interventionNames
- Other: SLC1A5 expression
- label
- paired adjacent tissues
- description
- SLC1A5 expression of paired adjacent esophageal tissues from patients
- interventionNames
- Other: SLC1A5 expression
Primary outcomes (1)
- measure
- optical density (ODs) of each slice by immunohistochemistry assay
- timeFrame
- within one year (plus or minus 1 month) after surgery
- description
- For immunohistochemistry assay： Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with histologically proven esophageal cancer; 2. Age ≥18 years; 3. All patients must sign consent forms voluntarily; Exclusion Criteria: 1. Inability to obtain histologic proof of malignancy. 2. Age \<18 years;
References
Publications (0)
Data not yet available
No reference posted for this study.